

Save the Date

# Diabetes & Endocrine Updates 2026 and 2<sup>nd</sup> International Conference on Diabetic Kidney Disease

**Naples, March, 25-26-27-28, 2026**

**Hotel Royal Continental**

*Scientific Coordinators:*

**Dott. Silvio Settembrini, Prof. Giovambattista Capasso**

*CME Credits will be requested*

## TOPICS

### DRUGS DISCOVERY AND RESEARCH

- In Silico Pharmacology. New Technology
- Computational approaches modelling and simulation in drug design
- Multiscale analysis of bioactive substances
- Ligand-Target Interactions. Docking Procedure
- Cutting-Edge molecular and multiscale modelling
- Big data methods in drug discovery and development

### DIABETES

- Molecular Biology and Physiology of Incretins
- Hormonal Control of Glucose Homeostasis
- Type 1 Diabetes: which new therapeutical perspective
- Type 2 Diabetes: Forefront in Early Interventions
- Aging and Cognitive decline by Glucotoxicity
- New Drugs for New Targets
- Advanced Technology in Glycemia Control and Therapy (*CGM and Pumps Systems*)

### ENDOCRINE

- Gut Endocrinology, a Network System. Entero-Endocrine Hormones from Physiology to Molecular Pharmacology
- Thyroid-Kidney, Thyroid-Liver links: a synergy for metabolic control
- The Microbiota as Endocrine Organ
- GLP1 – GIP – GLUCAGON –PYY... other hormones together for therapies?
- The Bone and Cardio-Renal Connections
- Testis and Ovary in Metabolic and Cardio-Vascular Balancing
- Aldosterone Over-Activation and Organs damage . New Discoveries from Selective Receptors Antagonism to Clinical Trials

### KIDNEY, DIABETIC KIDNEY DISEASE (DKD), CHRONIC KIDNEY DISEASE (CKD)

- Diabetic Kidney Disease: a Journey from I to V stage
- Molecular pathway of Glucotoxicity to Kidney Damage
- Spatial Metabolomics in DKD & CKD
- Genetic , Genomics and Phenotypes in DKD & CKD
- Renal Epithelial-Mesenchymal Transitions and Fibrosis
- Mitochondria role in DKD & CKD
- Clinical Settings in DKD-CKD: Cognitive Impairment, Heart Failure, Fertility & Sexuality, Dialysis New Technologies.
- Drugs Innovations and Research in Kidney Protection

### HEART

- Heart Failure. Pathway to Goals, Clinical and Therapeutical Targets
- From SCA to Heart Failure: a broken path to enhanced therapy
- SCA Physiopatology and Treatment
- HFrEF and HFpEF, Clinical Diagnostic and Therapeutical Differences
- Coronary and Miocardial Imaging, New Technology
- New Perspectives for Drugs Therapies

### LIVER

- Liver : Endocrine Organ, Endocrine Target
- Liver as Metabolic Gate-Keeper
- From NASH to MASLD. What changes in diagnostic framing
- Treating the Liver to treat the patient complexity : new drugs on coming

### OBESITY

- The Adipocyte, what's new to understand: an universe to be discovered
- Activate Lipolysis, Inhibit Liposynthesis, Pharmacological Targets for weight loss
- Clinical Settings of Obese Patients: Heart Failure, CKD, CVD Disease, Osteo-Arthrosis, Fertility-Sexuality.
- Next Frontiers: how to prevent weight regain after stop drugs for Obesity

### DYSLIPIDEMIA

- New Objectives for Clinical Management of Dyslipidemia
- Lp(a) Lipoprotein: a new, innovative C.V. target, for Drugs Discovery
- New drugs on the way: Selective Inhibitor of Lp(a) Muvalaplin; Small interfering RNA (siRNA) of Lp(a) Lepodisiran.
- Statins, PCSK9 inib. siRNA , Bempedoic Ac. , and others: how many drugs in combination therapy? How and Why.

### HYPERTENSION

- Hypertension: what is it and how did it start?
- We need new drugs? Why? How many and what?
- Hypertension, Physiopatological History for understand it's Complications
- To Treat Hypertension in Clinical settings of Increasing complexity

### NUTRITION NUTRACEUTICALS NUTRIGENOMICS

- Food and Microbiota Health
- Nutraceuticals for weight loss, is a concrete perspective?
- Nutraceuticals for Metabolic disease and C.V. control: comparable to drugs?
- Can we expect new clinical developments from Nutrigenomics?

### NEW FRONTIERS IN PHARMACOLOGICAL INNOVATIONS AND THERAPIES

- What have changed the historical trials for therapies of diabetes, renal, cardiac liver, brain, disease?
- We need new therapies for Metabolic Control and C.V. risk? Yes, but on which new targets?
- Comparison of drug classes in Medicine History and C.V. Management: ACEi, ARBs, SGLT2 inib., GLP1, GLP1-GIP, GLP1-GIP-Glucagon, GLP1-Glucagon Agonists, GLP1-Cagrilintide Ag., GIP inhibitors, Insulins Analogs with GLP1 Combinations, Aldosterone Receptor Antagonists and Synthase Inhibitors, Endothelin Receptor Antagonists, Neprilysin Inib., ANP-BNP-CNP derivative drugs, Soluble guanylate cyclase (sGC) stimulators, Others.